Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-29

DEVELOPMENT OF NOVEL ANIMAL MODELS OF GLUTAMATERGIC CENTRAL NERVOUS SYSTEM DISORDERS USING IN VIVO SIRNA AND TRANSGENIC APPROACHES

Objective

Glutamate is the most abundant excitatory transmitter in the brain. However, very few models exist to explore the potential of drugs that modulate glutamate transmission. Because altered glutamate transmission is involved in numerous psychiatric diseases, there is a strong need for such models, to characterise the effects of hypo- and hyper-glutamatergic states on the onset and development of such diseases. AGLAEA will develop and characterise models of selective, partial knockdown of specific components of the brain glutamatergic system in mice. This will provide better comprehension of the implication of glutamate signalling in diseases such as schizophrenia, anxiety and cognitive disorders. AGLAEA will lead to breakthrough research on the neurobiological and neurochemical bases of psychiatric disorders and will enable the further testing of new drugs for treatment. In order to selectively turn off specific components of the glutamatergic pathways, an siRNA approach will be used. The effect of modulation of glutamate signalling will be characterised using functional MRI (fMRI) and microdialysis/microsensor analysis. Specific behavioural tests will be carried out on live animals for the assessment of glutamate-related psychiatric disorders. Furthermore, the data collected from siRNA experiments will be applied to the generation of transgenic mice, in which modulation of glutamate signaling will be induced at different stages of development. Therefore, AGLAEA will provide both the pharmaceutical and the academic world with potent models. These models will be used to test novel compounds and assess their therapeutic value and will benefit researchers investigating the neurobiological and neurochemical bases of those diseases.
The consortium set up to reach the objectives of AGLAEA gathers 3 high tech SMEs, 2 academic groups and one large group for the management of the project (ALMA), representing all together 4 European countries (FR, HU, UK, NL).

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

STREP - Specific Targeted Research Project

Coordinator

ADDEX PHARMACEUTICALS FRANCE SAS
EU contribution
No data
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (5)

My booklet 0 0